Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

FLUCONAZOLE

All products: Limited Use (codes 528)

Other products in the same Health Canada class (J02A, J02AC) — coverage varies; not interchangeable

  • Itraconazole (Sporanox): general benefit, Limited Use 570, Not a benefit
  • Voriconazole (Vfend): limited Use 399
  • Posaconazole (Posanol): not a benefit
  • Amphotericin b (Fungizone): general benefit
  • Ketoconazole (Nizoral): general benefit, Not a benefit
  • Caspofungin (Cancidas): not a benefit

1 more in the class list below

Diflucan P.O.S. · DIN 02024152 · 10mg/mL · oral liquid

Limited Use — Reason for Use code 528 requiredMarketed · checked 2026-09-20
StatusLimited Use — Reason for Use code 528 required
Write on scriptLU code 528 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 528
Reason for Use code 528 For patients who are unable to swallow or tolerate solid oral dosage forms. Coverage limit: LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Diflucan P.O.S. · DIN 02024152 Manufacturer: Pfizer Canada Inc.; listing date 1999-04-15 Health Canada: Marketed since 1995-12-31 · brand DIFLUCAN · ATC J02AC01 FLUCONAZOLE · form Powder for solution · route Oral · ingredients FLUCONAZOLE 50 MG/5ML · company Ec labs · schedule Prescription
Check this DIN again · Health Canada product record

Diflucan P.O.S.: Formulary list price $1.3654/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.3654 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18010 · Verify on the e-Formulary ↗ (DIN 02024152)

Source record
DIN 02024152: Diflucan P.O.S. Raw flags: sec12=Y, sec3=Y Item: 081204025; group id 8; item number 0010; lccId 00001; manufacturer id PFI Source form: O/L; strength: 10mg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.3654; ministry $1.3654 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02024152 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18010
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (08:12:04 Antifungals) and how they are covered

Matched class: 08:12:04 Antifungals

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMPHOTERICIN B Some products covered without a code (check the product listing): ITRACONAZOLE, KETOCONAZOLE, NYSTATIN, TERBINAFINE HCL 08:12:04 Antifungals

ITRACONAZOLE

· 5 products · General benefit (2), Listed, not a benefit (1), Limited Use, codes 570 (2) · strengths: 100mg, 10mg/mL · Cap, Oral Sol

VORICONAZOLE

· 6 products · Limited Use, codes 399 · strengths: 50mg, 200mg · Tab

POSACONAZOLE

· 7 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg, 40mg/mL · DR Tab, O/L

AMPHOTERICIN B

· 1 products · General benefit · strengths: · Inj Pd-50mg Pk

KETOCONAZOLE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 200mg · Tab

CASPOFUNGIN ACETATE

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mg/Vial · Inj-Vial Pk

MICAFUNGIN SODIUM

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mg/Vial, 100mg/Vial · Inj Pd-10mL Vial Pk

NYSTATIN

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 100000U/mL · O/L

TERBINAFINE HCL

· 8 products · Listed, not a benefit (1), General benefit (7) · strengths: 250mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:12:04
Full class listing Related classes: 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:16 Penicillins, 08:12:24 Tetracyclines, 08:12:28 Other Antibiotics, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS Treatment DIFLUCAN (fluconazole) is indicated for the treatment of: 1. Oropharyngeal and esophageal candidiasis. DIFLUCAN is also effective for the treatment of serious systemic candidal infections, including urinary tract infection, peritonitis, and pneumonia. 2. Cryptococcal meningitis. 3. Prevention of the recurrence of cryptococcal meningitis in patients with acquired immunodeficiency syndrome (AIDS). Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly. Prophylaxis DIFLUCAN is also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. 1.1 Pediatrics (<18 years of age) Based on the data submitted and reviewed by Health Canada, the safety and efficacy of DIFLUCAN in pediatric patients ha… https://pdf.hres.ca/dpd_pm/00085459.PDF PM date: 2026-07-21 Source product: DIFLUCAN; DIN 02024152; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.